Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Description of new transcriptional profiles associated with risk of relapse and identification of specific sites of relapse in non-small cell lung cancer, toxicity and resistance to adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC).

Detailed Description
-----------------
A first blood sample will be taken during the week before the operation. A second blood sample will be taken 4 to 8 weeks after the operation. And in case of relapse, a third sample will be taken. These samples are going to be stored in the collection of biological resources of Angers. Concerning the biopsy of the resected NSLCL, it will be sent to the collection of biological resources of Angers for conservation directly next to the surgery.

Official Title
-----------------
Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subject Subject who received resection with primary non-small cell lung cancer at the University Hospital of Angers and whose tumor samples will be stored in collection of biological resources of University Hospital of Angers A written inform consent. Exclusion Criteria: Under 18 year old; Pregnant or nursing women; Deprived of liberty; Age under curatorship or guardianship; Unable to consent person; About not carrying a non-small cell lung cancer.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | 6 to 8 weeks after surgery | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 1 year | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 2 years | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 3 years | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 4 years | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 5 years | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 6 years | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 7 years | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 8 years | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 9 years | 
| Determination of news microarrays profiles of NSCLC relapse risks | The news microarrays profiles of NSCLC relapse risks will : assessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk) assessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient assessing the prediction of sites most likely metastatic relapse to guide survey strategy. | At 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-small cell lung cancer, adjuvant chemo-therapy, DNA chip